Fig. 3

The durability of antibody responses to predominant PvMSP8 peptides. a–d The frequencies of antibody responses to PvMSP8 peptide Nos. 2, 3, 4 and 5 in patients with an acute P. vivax infection (n = 16) compared to HC (n = 16). e–g Antibody responses to PvMSP8 peptides in seropositive patients, peptide No. 2 (n = 6), peptide No. 3 (n = 7), and peptide No. 5 (n = 5), at acute infection and three follow-up times in the cohort study (AC, 3 months, 9 months and 12 months post-infection). The cut-off value was calculated as the mean plus 2 SDs of the OD for HC